Immunocore heads toward H2 2026 dose data on second PRAME bispecific
IMC-P115C's Phase 1 safety and tolerability readout, expected in the second half of 2026, will test whether Immunocore's half-life-extended PRAME candidate can extend a franchise built on brenetafusp.
Executive Summary
- Immunocore plans to present first clinical data from a Phase 1 trial of a half-life-extended PRAME-targeting bispecific, widening its read on a target the company already advances through a later-stage asset.
- The trial is designed to characterize dose-limiting toxicities and adverse-event rates in a dose-escalation population, not to demonstrate tumor response, so the near-term readout speaks to tolerability rather than proof of efficacy.
- No other industry-sponsored Phase 1 trial targets PRAME in this advanced-cancer population, leaving the asset without a direct same-phase comparator even as the company's own longer-running PRAME program provides internal precedent.
- The trial has recruited toward its enrollment target without amendment or delay, indicating the operational risk profile is unremarkable heading into the disclosure window.
The catalyst
Immunocore disclosed at the J.P. Morgan Healthcare Conference on January 9, 2026, that it expects to share initial data from IMC-P115C, its PRAME-A02 half-life-extended candidate, in the second half of 2026, alongside data on brenetafusp combinations in ovarian and lung cancer. David Berman, the company's head of research and development, said the IMC-P115C data "will inform next development steps". The trial behind that data, NCT07156136, is a Phase 1 dose-escalation study enrolling HLA-A*02:01-positive patients with PRAME-positive advanced or metastatic tumors who have exhausted other therapies. Immunocore+1Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare ConferenceJan 9, 2026Study of IMC-P115C in Advanced PRAME-Positive CancersNCT07156136
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial measures
The trial's four primary endpoints are the percentage of participants with dose interruptions, reductions, or discontinuations, adverse events, dose-limiting toxicities, and serious adverse events, the standard battery for a first-in-human dose-finding study. Secondary endpoints include best overall response and progression-free survival by RECIST v1.1, along with pharmacokinetics and anti-drug antibody formation. Because the primary measures are all safety and tolerability metrics, the H2 2026 presentation is built to establish a workable dose and manageable toxicity profile, information value that precedes any efficacy claim rather than substitutes for one. NCT07156136Study of IMC-P115C in Advanced PRAME-Positive CancersNCT07156136
Trial status
The study is recruiting across sites in Spain, Australia, France, and Italy, targeting 140 patients, with a primary completion date of September 30, 2027, and a full completion date of August 30, 2029. Enrollment has held flat at its 140-patient target with no change recorded, and the trial has logged no protocol amendments to its endpoints or eligibility criteria since it opened, a pattern the underlying registry-churn metric characterizes as stable. First patient dosing occurred in December 2024, roughly two years before the data-presentation window opens. NCT07156136Study of IMC-P115C in Advanced PRAME-Positive CancersNCT07156136
Where it sits competitively
No other industry-sponsored Phase 1 trial targets PRAME specifically in advanced tumors, making IMC-P115C the only asset in that precise target-indication pairing at this stage. The company's own brenetafusp, a PRAME-targeting bispecific in a different format, has already advanced into a Phase 3 trial in first-line melanoma and a Phase 2 program nearing completion in October 2026, giving Immunocore an internal precedent for how its PRAME mechanism performs at later stages even though that program targets a different tumor type and modality than IMC-P115C's advanced-cancer, half-life-extended design. Beyond Immunocore's own programs, PRAME-directed cell therapies and vaccines from sponsors including Immatics, Marker Therapeutics, TScan Therapeutics, and GlaxoSmithKline have tested the target across other indications and modalities, but none shares IMC-P115C's specific combination of half-life-extended bispecific format and multi-tumor, PRAME-positive advanced-cancer population.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.